Janssen Research & Development, Llc

This study tests a drug combination (daratumumab plus chemotherapy) in people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. It focuses on heart safety and how the drug works in different racial groups. About 151 participants will …

This study tests an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for 12 weeks, and doctors m…

This early-stage study tests combinations of daratumumab (a targeted antibody) with two other drugs (talquetamab and teclistamab) in 290 adults with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. Part…

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo (inactive pill), or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal…

This study tests an experimental drug called JNJ-63723283, which helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others. The goal is to find the best dose and see if the drug can shrink tumors. About 413 participants …

This study tests a drug called erdafitinib against standard treatments (chemotherapy or pembrolizumab) in people with advanced bladder cancer that has specific FGFR gene changes. The goal is to see if erdafitinib helps people live longer. About 629 adults whose cancer worsened af…

This program offers early access to TAR-200, an experimental treatment, for people with high-risk non-muscle invasive bladder cancer who have run out of standard options. Participants must have tried all other treatments and cannot join a clinical trial. The goal is to provide tr…

This study tests a combination of two drugs (talquetamab and teclistamab) that help the immune system attack myeloma cells. It involves 228 adults with relapsed or refractory multiple myeloma, including those with tumors outside the bone marrow. The goal is to find the best dose,…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to 18 with Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a previous ustekinumab study and shown benefit from the drug. The main goal is to m…

This study tests a drug called guselkumab for children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. About 120 participants receive either the study drug, a placebo, or an active comparator to see how well it clears the skin …

This study tests whether the drug daratumumab can delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. About 390 people with high-risk smoldering myeloma received either daratumumab injections or were simply monitored. The goal is to see if the …

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a specific type of advanced lung cancer (EGFR exon 20 insertion mutation) live longer without their cancer growing. About 308 adults with non-small cell lung cancer that has spread wil…

This early-stage study tests a drug called apalutamide in 19 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check how the drug moves through the body and to see if it is safe. Researchers will also me…

This study tests an experimental drug called JNJ-77242113 for people with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. About 684 adults will receive either the drug or a placebo to see if it clears or greatly improves their skin. The trial als…

This study looks at men with metastatic prostate cancer that still responds to hormone therapy. After 6 months of standard treatment, some men will take breaks from the hormone therapy to see if it reduces hot flashes without allowing the cancer to grow back faster. The goal is t…

This early-stage study tests a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug is an antibody carrying a radioactive payload that targets a protein found on prostate cancer cells.…

This study looks at whether special skin care can lower the chance of bad rashes and other skin problems in people with advanced lung cancer who are taking two drugs (amivantamab and lazertinib). About 305 patients will be assigned to different skin care routines to see which wor…

This study tests whether guselkumab, a targeted injectable drug, can reduce joint pain and swelling in people with active psoriatic arthritis who did not get enough relief from or could not tolerate a common first-line treatment (anti-TNF therapy). About 450 adults with active di…

This study tests a drug called guselkumab in 350 people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if it can reduce symptoms and heal the gut lining. Participants receive either the drug or a placebo, and researchers…

This early-stage study tests a new drug called amivantamab, alone or with other treatments, in people with advanced non-small cell lung cancer that has spread or cannot be removed. The goal is to find safe doses and see if the drug shrinks tumors. About 751 participants are invol…

This study follows 97 people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss, after they received a gene therapy called AAV5-hRKp.RPGR. Researchers are checking for side effects and measuring changes in eyesight over time. The goal is to see if t…

This study tests whether a new drug combination (TAR-200 plus cetrelimab) can help people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. About 518 participants will receive either the drug combo or standard chemoradiation. The goal is …

This study tests a drug called guselkumab in over 1,000 people with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if it can reduce symptoms like diarrhea and bleeding and help the gut heal. Participants receive either the drug or a placebo, an…

This study tests a drug called golimumab in 84 children with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (fewer symptoms) within 6 weeks and m…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) helps people with untreated multiple myeloma achieve deeper cancer remission. About 395 participants who are not eligible for a stem cell transplant …

This early-phase study tests a new drug called JNJ-88998377 in about 58 people with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will be cl…

This study tests a drug called erdafitinib, which targets specific gene changes in cancer cells, for people with advanced bladder cancer that has spread. It involves about 125 participants and looks at safety and how well the tumor shrinks when erdafitinib is used alone or with o…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The goal is to see if the drug reduces joint pain, swelling, and skin symptoms better than a placebo. Participants …

This study tests a drug called apalutamide in Chinese men with a type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread yet. The goal is to see if the drug can delay a rise in PSA levels, a key sign of cancer progression, compared to a p…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) live longer without the cancer growing. The study includes 776 adults wh…

This study tests whether a combination of two drugs, amivantamab and lazertinib, works better than the standard drug osimertinib for people with advanced non-small cell lung cancer that has certain EGFR gene mutations. About 1,074 participants who have not had prior treatment wil…

This study compares a new oral blood thinner, milvexian, to the standard drug apixaban in about 20,000 adults with atrial fibrillation (an irregular heartbeat). The goal is to see if milvexian is at least as good at preventing strokes and blood clots, while also checking for blee…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This study tests two experimental treatments—TAR-200 (a drug placed directly into the bladder) and cetrelimab (an immunotherapy injection)—alone or together in 220 people with high-risk bladder cancer that did not get better after standard BCG therapy. Participants are those who …

This study tests two different doses of an experimental drug called erdafitinib in people with advanced bladder cancer that has spread or cannot be removed by surgery and has certain FGFR gene changes. The main goal is to see how well the drug shrinks tumors. About 239 participan…

This early-stage study tests a new drug combination (JNJ-80948543 plus JNJ-75348780) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safest dose an…

This study tests a drug called guselkumab in over 1,000 people with active psoriatic arthritis (PsA). The goal is to see if it reduces pain, swelling, and slows joint damage compared to a placebo. Participants receive injections under the skin, and the study is in its final phase…

This study tests a new drug called talquetamab for people with multiple myeloma that has come back or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find a safe dose and check for side effects in abou…

This large Phase 3 study tests whether a daily oral medication called milvexian can lower the chance of having another stroke in people who recently had a mild stroke or a high-risk mini-stroke. Over 12,500 participants are randomly assigned to receive either milvexian or a place…

This early-stage study tests a combination of two types of immune-based drugs (bispecific antibodies and a checkpoint inhibitor) in people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find safe doses and understand side effects.…

This early-stage study tests a new drug called bleximenib combined with standard leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 part…